Targeted pill trial aims to halt growth in Tough-to-Treat cancers
NCT ID NCT06385496
Summary
This study is testing if an oral drug called MLN0128 can help control advanced cancers that have a specific genetic change (mTOR mutation) and have stopped responding to other treatments. About 35 patients with various advanced cancers, including solid tumors, lymphoma, or myeloma, will take the pill daily. The main goal is to see if the drug shrinks tumors or stops them from growing by blocking a key enzyme that cancer cells need.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.